TG103

DRUG5 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Conditions

HealthyType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

A Study of TG103 in Chinese Healthy Adult Subjects

CompletedNCT03990090

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy

Start: 2019-07-29End: 2020-11-11Updated: 2020-11-24

A Study of TG103 in Subjects With Type 2 Diabetes

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Type 2 Diabetes

Start: 2021-04-30End: 2022-03-31Target: 54Updated: 2021-03-10

Phase 2

A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Type 2 Diabetes Mellitus

Start: 2021-10-31End: 2024-03-31Target: 208Updated: 2021-10-01

Phase 3

A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

CompletedNCT06235086

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Type 2 Diabetes Mellitus

Start: 2024-04-08End: 2026-02-03Updated: 2026-04-03

A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus

CompletedNCT06258148

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Type 2 Diabetes Mellitus

Start: 2024-04-15End: 2026-01-23Updated: 2026-03-31

Related Papers

Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.

2024-05-293 citations

Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects

European Journal of Pharmaceutical Sciences2023-04-148 citations